Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etranacogene dezaparvovec - CSL Behring

Next Previous
X
Search
Drug Profile

Etranacogene dezaparvovec - CSL Behring

Alternative Names: AAV5-FIX-Padua; AAV5-hFIXco-Padua; AMT 061; CSL-222; Etranacogene dezaparvovec - CSL Behring/uniQure; Etranacogene dezaparvovec-drlb; EtranaDez; HEMGENIX; Lanacogene vosiparvovec

Latest Information Update: 19 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator uniQure
  • Developer CSL Behring
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor IX replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 16 Jul 2024 CSL Behring announces that the Canadian Agency for Drugs and Technologies in Health (CADTH) recommends public drug plan reimbursement for etranacogene dezaparvovec (HEMGENIX®) for the treatment of adults with hemophilia B
  • 15 Mar 2024 Registered for Haemophilia B in Australia (IV)
  • 28 Feb 2024 UniQure owns a patent family, including patents and patent applications, directed to the use of the Padua mutation in human Factor IX (“hFIX”) for gene therapy in etranacogene dezaparvovec
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top